Afatinib overcoming resistance to icotinib and osimertinib in NSCLC with leptomeningeal metastasis in patients with acquired EGFR L858R/T790M or L858R/S768I mutations: Two case reports

BACKGROUND: Advanced non-small cell lung cancer (NSCLC) is often complicated by leptomeningeal metastases (LMs), especially in patients carrying EGFR mutations. EGFR tyrosine kinase inhibitors (TKIs) are the first-line drug for patients with specific gene mutations, such as EGFR exon 19 deletion or...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Guangrui, Fang, Mei, Zhou, Yazhu, Liu, Xiaocui, Tian, Panpan, Mei, Fengjun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582297/
https://www.ncbi.nlm.nih.gov/pubmed/37860534
http://dx.doi.org/10.1016/j.heliyon.2023.e20690

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582297/
https://www.ncbi.nlm.nih.gov/pubmed/37860534
http://dx.doi.org/10.1016/j.heliyon.2023.e20690

Ejemplares similares